Recombinant Human KRT19 293 Cell Lysate

• Cat.No.: KRT19-4875HCL

Specification

• Description: Antigen standard for keratin 19 (KRT19) is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection.
• Source: HEK 293 cells
• Species: Human
• Components: This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol).
• Size: 0.1 mg
• Storage Instruction: Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored at -20°C. Product is guaranteed 6 months from the date of shipment.
• Applications: ELISA, WB, IP. WB: Mix equal volume of lysates with 2X SDS Loading Buffer. Boil the mixture for 10 min before loading (for membrane protein lysates, incubate the mixture at room temperature for 30 min). Load 5 ug lysate per lane.
• Tag: Non

Gene Information

• Gene Name: KRT19 keratin 19 [ Homo sapiens ]
• Official Symbol: KRT19
• Synonyms: KRT19; keratin 19; keratin, type I cytoskeletal 19; 40 kDa keratin intermediate filament; CK19; cytokeratin 19; K1CS; K19; keratin; type I cytoskeletal 19; type I; 40 kd; MGC15366; CK-19; keratin-19; cytokeratin-19; keratin, type I, 40-kd; 40-kDa keratin intermediate filament
• Gene ID: 3880
• mRNA Refseq: NM_002276
• Protein Refseq: NP_002267
• MIM: 148020
• UniProt ID: P08727
• Chromosome Location: 17q21-q23
• Pathway: Signaling mediated by p38-alpha and p38-beta, organism-specific biosystem
• Function: protein binding; structural constituent of cytoskeleton; structural constituent of muscle

Reviews

08/25/2021

Such support helps researchers overcome challenges and obtain reliable results.

11/22/2020

This flexibility allows researchers to focus on specific aspects of KRT19 protein functionality, regulation, or disease associations, enhancing the relevance and applicability of their work.

08/26/2020

Manufacturers might offer customization options, such as different variants or modifications of the KRT19 protein, to cater to specific research requirements.

Q&As

Are there any clinical trials involving KRT19 protein?

Yes, there are ongoing clinical trials exploring the use of KRT19 as a biomarker and its potential as a therapeutic target in cancer treatment.

Are there any non-cancer clinical applications of KRT19?

Yes, KRT19 can also be used as a biomarker in other diseases, such as liver diseases and rheumatoid arthritis.

Are there any targeted therapies based on KRT19 expression?

Some targeted therapies are being developed that specifically target cancer cells with high KRT19 expression.

Can KRT19 protein be used to predict the prognosis of cancer patients?

Yes, KRT19 expression levels can provide information about the prognosis of cancer patients, helping in treatment planning.

How is KRT19 protein detected in clinical samples?

KRT19 protein can be detected using various laboratory techniques, including immunohistochemistry, ELISA, and PCR.